|
41 |
Loss of CD22 expression and expansion of a CD22dim subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin
Enthalten in Annals of hematology Bd. 100, 31.7.2021, Nr. 11, date:11.2021: 2727-2732
|
|
|
|
42 |
Pretransplant spleen volume and outcome after hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML)
Enthalten in Annals of hematology Bd. 102, 10.7.2023, Nr. 9, date:9.2023: 2543-2553
|
|
|
|
43 |
PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation
Enthalten in Blood cancer journal Bd. 14, 15.3.2024, Nr. 1, date:12.2024: 1-8
|
|
|
|
44 |
Real world outcome analysis of treosulfan-based conditioning prior to allo-HCT in patients with MDS compared to clinical trial data
Enthalten in Bone marrow transplantation Bd. 60, 5.11.2024, Nr. 1, date:1.2025: 103-106
|
|
|
|
45 |
The role of autologous stem cell transplantation (ASCT) in aggressive B-cell lymphomas: real-world data from a retrospective single-center analysis
Enthalten in Annals of hematology Bd. 100, 3.9.2021, Nr. 11, date:11.2021: 2733-2744
|
|
|
|
46 |
Thiotepa–fludarabine–treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial
Enthalten in Bone marrow transplantation Bd. 57, 18.8.2022, Nr. 11, date:11.2022: 1664-1670
|
|
|
|
47 |
Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT
Enthalten in Blood cancer journal Bd. 9, 12.4.2019, Nr. 4, date:4.2019: 1-7
|
|
Administration
